Author: Kai Duan; Bende Liu; Cesheng Li; Huajun Zhang; Ting Yu; Jieming Qu; Min Zhou; Li Chen; Shengli Meng; Yong Hu; Cheng Peng; Mingchao Yuan; Jinyan Huang; Zejun Wang; Jianhong Yu; Xiaoxiao Gao; Dan Wang; Xiaoqi Yu; Li Li; Jiayou Zhang; Xiao Wu; Bei Li; Yanping Yu; Wei Chen; Yan Peng; Yeqin Hu; Lianzhen Lin; Xuefei Liu; Shihe Huang; Zhijun Zhou; Lianghao Zhang; Yue Wang; Zhi Zhang; Kun Deng; Zhiwu Xia; Qin Gong; Wei Zhang; Xiaobei Zheng; Ying Liu; Huichuan Yang; Dongbo Zhou; Ding Yu; Jifeng Hou; Zhengli Shi; Saijuan Chen; Zhu Chen; Xin-xin Zhang; Xiaoming Yang
Title: The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study Document date: 2020_3_23
ID: 8znnq0rh_42
Snippet: Furthermore, some patients received glucocorticoid therapy, which might interfere with immune response and delay virus clearance. Second, the median time from onset of symptoms to CP transfusion was 16.5 days (IQR11.0-19.3 days). Although the kinetics of viremia during natural history remains unclear, the relationship between SARS-CoV-2 RNA reduction and CP therapy, as well asthe optimal concentration of neutralizing antibodies and treatment sche.....
Document: Furthermore, some patients received glucocorticoid therapy, which might interfere with immune response and delay virus clearance. Second, the median time from onset of symptoms to CP transfusion was 16.5 days (IQR11.0-19.3 days). Although the kinetics of viremia during natural history remains unclear, the relationship between SARS-CoV-2 RNA reduction and CP therapy, as well asthe optimal concentration of neutralizing antibodies and treatment schedule, should be further clarified. Third, the dynamic changes of cytokines during treatment were not investigated.
Search related documents:
Co phrase search for related documents- cp therapy and immune response: 1, 2, 3, 4, 5, 6, 7
- cp therapy and median time: 1, 2, 3, 4, 5, 6, 7
- cp therapy and symptom onset: 1, 2, 3
- CP transfusion and day day: 1, 2, 3, 4
- CP transfusion and immune response: 1
- CP transfusion and median time: 1, 2, 3, 4, 5, 6, 7, 8
- CP transfusion and symptom onset: 1, 2, 3, 4, 5, 6
- day day and dynamic change: 1, 2, 3, 4
- day day and glucocorticoid therapy: 1, 2
- day day and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- day day and median time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- day day and natural history: 1, 2, 3, 4, 5, 6, 7
- day day and neutralize antibody: 1
- day day and symptom onset: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- delay immune response and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- dynamic change and immune response: 1, 2, 3, 4, 5, 6
- dynamic change and median time: 1
- dynamic change and symptom onset: 1, 2
- glucocorticoid therapy and symptom onset: 1, 2
Co phrase search for related documents, hyperlinks ordered by date